Skip to content
‹ Back to IndustriesSciences

AI Failed At Writing Sci-Fi. Here’s Why Publishers May Just Want Them to Succeed

Recently, science fiction magazine Clarkesworld was forced to close submissions for authors after being flooded with stories written by AI tools. While it was clear that the AI failed at writing sci-fi, this failure pointed towards larger problem: AI-assisted plagiarism. Neil Clarke, the editor of Clarkesworld, said the amount of spam the magazine typically…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Darren Campo · Alex DetailAsimov’s Science FictionChatgptClarkesworld
Share

Key takeaways

01

Recently, science fiction magazine Clarkesworld was forced to close submissions for authors after being flooded with stories written by AI tools.

02

While it was clear that the AI failed at writing sci-fi, this failure pointed towards larger problem: AI-assisted plagiarism.

03

Neil Clarke, the editor of Clarkesworld, said the amount of spam the magazine typically…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Recently, science fiction magazine Clarkesworld was forced to close submissions for authors after being flooded with stories written by AI tools. While it was clear that the AI failed at writing sci-fi, this failure pointed towards larger problem: AI-assisted plagiarism.

Neil Clarke, the editor of Clarkesworld, said the amount of spam the magazine typically receives has increased drastically since ChatGPT was launched. The culprits, he believes, are not authors themselves — but rather, people who want to take advantage of the sci-fi community’s higher rates for authors and always-open submission windows.

Clarkesworld is not the only sci-fi magazine facing this problem. Asimov’s Science Fiction has also been receiving similar AI submissions. Some of them were so obviously written by AI that they actually had the same title.

While the AI tools failed at writing sci-fi, they are likely to improve with time. However, some experts believe the publishing world need not be worried, as improved technology and new cutting edge tools for creating or publishing written content has generally had a positive impact on readers and writers. Darren Campo, Senior Vice President of Programming and Content Strategy for The Food Network and Cooking Channel, Adjunct Assistant Professor at the NYU Stern School of Business, and author of the sci-fi series Alex Detail, tells us why anything (even disruptive technology) is great for the publishing world if it increases readership.

Darren’s Thoughts:

Science fiction magazines that publish short stories are now being inundated by stories written by AIs like Chat GPT. This is according to a recent article from The New York Times where they spoke to the editors at sci-fi magazines like Clarkesworld and Asimov’s Science Fiction. Now, according to the editors so far, these stories aren’t very good. They’re pretty easy to spot. They read more like a list of facts in a simple story format rather than something that a writer developed in his/her craft has written. However, it really won’t be long before AI is able to generate stories that are interesting to some people to read. So, how does this impact the publishing world?

Well, first we should ask, ‘How does this impact the reader? How has technology impacted readership in the past?’ A couple of big examples are the technologies that enabled for self-publishing. With self-publishing, we had books about subjects and characters that were not widely written about before, and that was great for readers. Another technology that allowed for the distribution of fan fiction over the internet led to things like 50 Shades of Grey, which was the highest selling book of its decade and inspired thousands of book clubs, movies about those book clubs, and other movies. So, that was also generally a net positive for both the reader and the publishing world.

So as this disruptive technology unfolds, it will eventually be a positive for the reader and anything that’s good and increases readership is great for the publishing world as well. As a science fiction writer myself, I am really looking forward to seeing how this all unfolds over the next few years.”

Article written by Aarushi Maheshwari.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Darren Campo
Darren CampoAdjunct Professor of Media & Technology

Darren Campo is an Adjunct Professor of Media & Technology at NYU's Stern School of Business. He's a seasoned producer, media executive, and bestselling novelist. Campo has held significant roles in programming, development, and production for networks such as Food Network, Cooking Channel, TruTV, and Court TV. Darren played a pivotal role in the creation of and programming development for TruTV of TimeWarner, and has been involved in the production and development of hundreds of shows. He is also the author of novels like "Alex Detail’s Revolution" and "Disappearing Spell."

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Clinical data harmonization is the bottleneck for life sciences AI

Clinical data harmonization is the bottleneck for life sciences AI

Life sciences companies moving AI from experimentation to scale keep running into messy trial data. One study can draw on EDC, health records, eCOA tools, wearables and imaging, and data teams at pharma SMEs often spend up to 80% of their time wrangling it. Commentators point to lakehouse architectures and data-cleansing AI agents, though the agents are still at proof of concept.

  • 01Treat automation gains as proof-of-concept for now; evaluate AI/harmonization choices based on data readiness, governance, and whether the architecture supports traceability and regulatory needs.

Sep 26, 2026

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Darren Campo
Darren Campo

Adjunct Professor of Media & Technology

Darren Campo is an Adjunct Professor of Media & Technology at NYU's Stern School of Business. He's a seasoned producer, media executive, and bestselling novelist. Campo has held significant roles in programming, development, and production for networks such as Food Network, Cooking Channel, TruTV, and Court TV. Darren played a pivotal role in the creation of and programming development for TruTV of TimeWarner, and has been involved in the production and development of hundreds of shows. He is also the author of novels like "Alex Detail’s Revolution" and "Disappearing Spell."

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512